COVID-19
Conditions
Keywords
secondary infections, bacterial infections, fungal infections
Brief summary
Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are also called hospital acquired secondary infections. Patients who contract COVID-19 and require an ICU admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. In COVID-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. This study is evaluating the effect these medications have on the development of secondary infections and rate of survival of COVID-19 patients that have been admitted to ICUs.
Interventions
OTHERPreviously admitted COVID-19 patients in intensive care units
Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
Sponsors
Merck Sharp & Dhome (Australia) Pty. Ltd.
Christian Medical College, Vellore, India
Tan Tock Seng Hospital
Royal Brisbane and Women's Hospital
Siriraj Hospital
University of North Carolina, Chapel Hill
The University of Queensland
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hospital admission date from 1 July 2020 to 30 June 2021 * Positive test for COVID-19 collected within 1 week of admission date * ICU admission within 60 days after hospital admission date
Exclusion criteria
* Hospital admission shorter than 5 days * Persons younger than 18 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Describe the incidence, management and outcomes of secondary infections in COVID-19 patients admitted to intensive care units | Within the first 60 days of hospital admission | Data collected from medical records of patients will include demographics, medical history, details of bacterial and fungal infections in the first 60 days after admission (includes aetiological pathogen, sample isolated from and antimicrobial susceptibility), treatment received for COVID-19 with antiviral or immunomodulatory therapy and disposition at 60 days from hospital admission |
| Compare clinical and microbiological outcomes based on treatment appropriateness in COVID-19 patients admitted to intensive care units | Within the first 60 days of hospital admission | Data collected from medical records of patients will include demographics, medical history, details of bacterial and fungal infections in the first 60 days after admission (includes aetiological pathogen, sample isolated from and antimicrobial susceptibility), treatment received for COVID-19 with antiviral or immunomodulatory therapy and disposition at 60 days from hospital admission |
| Assess the use and effect of immune suppression in COVID-19 patients admitted to intensive care units. | Within the first 60 days of hospital admission | Data collected from medical records of patients will include demographics, medical history, details of bacterial and fungal infections in the first 60 days after admission (includes aetiological pathogen, sample isolated from and antimicrobial susceptibility), treatment received for COVID-19 with antiviral or immunomodulatory therapy and disposition at 60 days from hospital admission |
Countries
Australia, India, Singapore, Thailand, United States
Outcome results
None listed